Life Technologies

Kodiak focuses on companies in the areas of life sciences tools, diagnostics and medical devices. We seek opportunities where we can apply our broad experience in technology to help entrepreneurs bring high-impact solutions to market.

ALIS Logo

ALIS was acquired by Carl Zeiss SMT in July 2006.


Kodiak Partner: Dave Furneaux

 
Allegro Diagnostics, Inc Logo

Allegro Diagnostics was acquired by Veracyte in September 2014.


Kodiak Partner: Andrey Zarur

 
Fluxion Biosciences Logo

By characterizing molecular and cellular mechanisms in physiologically relevant micro-environments, Fluxion helps bridge the translational medicine gap by bringing research data closer to patients. Our innovative systems for live cell analysis are enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

www.fluxionbio.com 


Kodiak Partner: Dave Furneaux

 
GreenLight Biosciences Logo

GreenLight Biosciences, Inc. has developed a unique Cell-Free bioprocessing platform capable of producing RNA sequences of exceptional fidelity in a fully-scalable fashion at a fraction of the costs of other technologies. The company is focused on development of dsRNA-based products for crop agriculture, and is developing further RNA offerings in the areas of public health, vaccine development and human therapeutics. GreenLight has established partnerships with some of the world's leading chemical and agricultural companies to develop and commercialize its products. GreenLight is committed to helping reduce the harmful effects of chemical emissions into our environment and to doing its part in fighting global climate change. 

http://www.greenlightbiosciences.com/ 


Kodiak Partner: Dave Furneaux

 
Lumicell Logo

Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The LUM System includes three integrated components: a fluorescent optical contrast agent that is cancer- and immuno-activated, a novel hand-held imaging device that instantly scans the cavity walls to view the fluorescent cells with single-cell detection, and proprietary decision software that displays the image instantly on a monitor to guide surgical removal of cancerous tissue. The unprecedented ability to see and remove cancer cells remaining in the cavity – beyond the margin of the specimen – during the initial surgery has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include surgeries for lung, ovarian, and brain cancers.

 

http://www.lumicell.com/

 


Kodiak Partner: Dave Furneaux